Table 1.
Clinical characteristics of study subjects in each group
| Normal (n=15) | ATN (n=29) | AR (n=41) | Control (n=15) | |
|---|---|---|---|---|
| Male /female | 9/6 | 18/11 | 27/14 | 8/7 |
| Caucasian (%) | 40 | 41 | 34 | 47 |
| African American (%) | 27 | 59 | 61 | 53 |
| Others (%) | 33 | 0 | 5 | 0 |
| Age (yr)* | 42 ± 15.4 | 43 ± 16.2 | 46.5 ± 16 | 48 ± 17 |
| Body weight (kg)* | 75 ± 15 | 78 ± 17 | 77 ± 16 | 78 ± 16 |
| Serum Creatinine (mg/dL)* | 1.0 ± 0.1 | 3.9 ± 2.4** | 4.1 ± 3.0** | 1.2 ± 0.1 |
| Estimated GFR (ml/min)* | 73 ± 10 | 23 ± 11** | 21 ± 12** | 64 ± 15 |
| Cause of ESRD (%) | ||||
| HTN | 52 | 54 | 47 | |
| DM | 24 | 24 | 27 | |
| GN | 10 | 15 | 13 | |
| Others | 14 | 7 | 13 | |
| Previous transplant (%) | 21 | 22 | 13 | |
| Peak PRA (%)* | 20 ± 29 | 16 ± 31 | 17 ± 18 | |
| HLA mismatch* | 3.5 ± 1.1 | 4.2 ± 1.4 | 3.9 ± 1.2 | |
| Living donor (%) | 17 | 22 | 20 | |
| Deceased donor (%) | 83 | 78 | 80 | |
| Cold ischemia time (hrs)* | 16.4 ± 7 | 17.3 ± 6 | 16 ± 6.4 | |
| Immunosuppression (%) | ||||
| Baciliximab | 21 | 17 | 20 | |
| Antithymocyte globulin | 3.4 | 4.9 | 0 | |
| Tacrolimus | 62 | 59 | 53 | |
| Cyclosporine | 31 | 29 | 33 | |
| Mycophenolate | 90 | 80 | 93 | |
| Sirolimus | 10 | 12 | 7 | |
| Azathioprine | 7 | 10 | 13 | |
| Prednisone | 90 | 78 | 87 | |
*
Data are expressed as mean ± SD
**
P < 0.01 versus Normal and Control groups; ATN, acute tubular necrosis; AR, acute rejection; GFR, glomerular filtration rate; ESRD, end stage renal disease; HTN, hypertension; DM, diabetes mellitus; GN, glomerulonephritis; PRA, panel reactive antibody; HLA, human leukocyte antigen